You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023110014
Dec 202344010
Jan 202469012
Feb 20244804
Mar 20242404
Apr 20242009
May 20241602
Jun 20243201
Jul 2024403
Aug 20241205
Sep 20241803
Oct 20242207
Nov 20242406
Dec 20241803
Jan 20253206
Feb 20250010
Mar 20250010
Apr 2025006
May 2025006
Jun 2025004
Total4930125